Document is current

Article History

Received: 25 April 2023

Accepted: 15 June 2023

First Online: 30 June 2023

Declarations

:

: Not applicable.

: Not applicable.

: Diego Conti is the academic manager at EUFOREA. He has no competing interest to declare. Peter Hellings is consultant and recipient of lecture fees and/or research grants from Sanofi, Regeneron, Novartis, GSK, ALK, and Viatris. Zuzana Diamant received in the past three years speaker fees or honoraria or serving on advisory boards or as a consultant from Antabio, Boehringer Ingelheim, Foresee Pharmaceuticals, GlaxoSmithKline, QPS-Netherlands, Sanofi-Genzyme-Regeneron, all outside the submitted work. Leif Bjermer has no competing interest to declare in relation to this work. Milos Jesenak reports receiving consultancy/speaker honoraria from CSL Behring, SOBI, Novartis, GSK, Sanofi, Viatris, and Takeda Pharmaceutical Co. Ltd.; and serving as a principal investigator for clinical trials sponsored by Takeda, Mundipharma, Octapharma, BioCryst Pharmaceuticals, Inc. and Pharming Group NV. Vibeke Backer has no competing interest to declare in relation to this work. Wytske Fokkens has no competing interest to declare in relation to this work. Susanne Lau has received honoraria for lectures and AD Boards from Sanofi-Aventis, DBV, Allergopharma, ALK, Leti, GSK, and Leo Pharma in the last three years. Elizabeth Van Staeyen is the Scientific Communications & Advocacy Manager at EUFOREA. She has no competing interest to declare. Glenis Scadding is a Board member of EUFOREA. She has received remuneration from Sanofi Regeneron and has undertaken trials for GSK.